IHC - For confirming Metastatic tumor of Breast origin [ER, PR, GCDFP-15,Mammoglobin]

The IHC Panel for Confirming Metastatic Tumor of Breast Origin [ER, PR, GCDFP-15, Mammoglobin] is an advanced immunohistochemistry (IHC) diagnostic test used to identify whether a metastatic tumor has originated from breast tissue. This highly specialized panel helps pathologists confirm breast cancer spread when cancer cells are detected in distant organs or tissues.

Metastatic tumors can sometimes resemble cancers from other organs, making diagnosis difficult. This panel uses four important breast cancer markers—Estrogen Receptor (ER), Progesterone Receptor (PR), GCDFP-15 (Gross Cystic Disease Fluid Protein-15), and Mammoglobin—to accurately determine whether the tumor cells originated from breast tissue.

These markers work together to provide strong evidence of breast tissue origin, helping doctors distinguish metastatic breast carcinoma from cancers arising in the lung, ovary, liver, gastrointestinal tract, or other organs.

Benefits of the Test

This IHC panel offers several important clinical benefits:

• Confirms whether metastatic cancer originated from breast tissue
• Helps differentiate breast metastasis from other cancers
• Supports accurate cancer staging
• Guides oncologists in selecting targeted treatment plans
• Improves prognosis assessment and treatment monitoring

Accurate identification of tumor origin is essential for choosing the right therapy and avoiding incorrect treatment.

Why Doctors Recommend This Test

Doctors recommend this test when metastatic cancer is suspected but the primary source is unclear. It is commonly ordered when cancer cells are found in lymph nodes, bone, liver, lungs, or other tissues, and the patient has a history of breast cancer or suspicious imaging findings.

The panel helps oncologists confirm recurrence or spread of breast cancer and allows them to design personalized treatment strategies such as hormone therapy, chemotherapy, or targeted therapies.

Preparation Before Test

No direct patient preparation is required. The test is performed on biopsy or surgically removed tissue samples. Patients only need to follow standard instructions for sample collection procedures.

Normal Reporting Time

The typical reporting time for this IHC panel is 3 to 5 working days, depending on tissue processing complexity and laboratory workflow.

Who Should Take This Test

This test is recommended for:

• Patients with suspected metastatic breast cancer
• Individuals with metastatic tumors of unknown primary origin
• Patients with a history of breast carcinoma and possible recurrence
• Cases requiring confirmation of breast tissue origin
• Oncology patients undergoing advanced tumor profiling

The metastatic breast origin IHC panel is a critical diagnostic tool in modern oncology. By combining ER, PR, GCDFP-15, and Mammoglobin markers, it provides highly reliable evidence for breast-origin tumors and helps guide precise cancer treatment decisions.